# Anne S. Tsao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anne-s-tsao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,314 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 84 |
| i10-index | 201 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5057281549 |
| ORCID iD | https://orcid.org/0000-0003-0505-6639 |
| Works | 589 |

## Researcher papers

- [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/)
- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/)
- [The BATTLE Trial: Personalizing Therapy for Lung Cancer](https://scholariq.org/papers/the-battle-trial-personalizing-therapy-for-lung-cancer/)
- [Integrative Molecular Characterization of Malignant Pleural Mesothelioma](https://scholariq.org/papers/integrative-molecular-characterization-of-malignant-pleural-mesothelioma/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome](https://scholariq.org/papers/effect-of-kras-oncogene-substitutions-on-protein-behavior-implications-for/)
- [Mesothelioma: Scientific clues for prevention, diagnosis, and therapy](https://scholariq.org/papers/mesothelioma-scientific-clues-for-prevention-diagnosis-and-therapy/)
- [The Integrated Genomic Landscape of Thymic Epithelial Tumors](https://scholariq.org/papers/the-integrated-genomic-landscape-of-thymic-epithelial-tumors/)
- [First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-versus-chemotherapy-in-patients-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Occupational and environmental lung diseases](https://scholariq.org/topics/occupational-and-environmental-lung-diseases/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Pleural and Pulmonary Diseases](https://scholariq.org/topics/pleural-and-pulmonary-diseases/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.